Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin

European Journal of Pharmacology

Volumn 594, Issue 1-3, 2008, Pages 146-151

  Fujiwara, Takayuki ^a   Saito, Shin ^a   Osanai, Tomohiro ^a   Kameda, Kunihiko ^a   Abe, Naoki ^a   Higuma, Takumi ^a   Yokoyama, Jin ^a   Hanada, Hiroyuki ^a   Fukui, Kozo ^a   Fukuda, Ikuo ^a   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Coronary artery disease; Matrix metalloproteinase; Oxidative stress; Pravastatin

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; NICORANDIL; PRAVASTATIN; SPIRONOLACTONE;

AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART MUSCLE CELL; HUMAN; MALE; OXIDATIVE STRESS; PERICARDIUM; PLASMA; PRIORITY JOURNAL; ZYMOGRAPHY;

AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DINOPROST; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYOCARDIUM; OXIDATIVE STRESS; PERICARDIAL EFFUSION; PRAVASTATIN;

EID: 50649089372     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.07.039     Document Type: Article

References (33)

1. Abe N., Matsunaga T., Kameda K., Tomita H., Fujiwara T., Ishizaka H., Hanada H., Fukui K., Fukuda I., Osanai T., and Okumura K. Increased level of pericardial insulin-like growth factor-1 in patients with left ventricular dysfunction and advanced heart failure. J. Am. Coll. Cardiol. 48 (2006) 1387-1395
2. Brown D.L., Hibbs M.S., Kearney M., Loushin C., and Isner J.M. Identification of 92-kDa gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 91 (1995) 2125-2131
3. Cappola T.P., Kass D.A., Nelson G.S., Berger R.D., Rosas G.O., Kobeissi Z.A., Marbán E., and Hare J.M. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 104 (2001) 2407-2411
4. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 (2004) 39-43
5. 2a generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation 95 (1997) 2492-2499
6. Fujita M., Komeda M., Hasegawa K., Kihara Y., Nohara R., and Sasayama S. Pericardial fluid as a new material for clinical heart research. Int. J. Cardiol. 77 (2001) 113-118
7. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Unemori E.N., Lark M.W., Amento E., and Libby P. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res. 75 (1994) 181-189
8. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., Wen J., and Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
9. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., and Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J. 141 (2001) 211-217
10. Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., Ueno T., Sugi K., and Imaizumi T. Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 32 (1998) 368-372
11. Kameda K., Matsunaga T., Abe N., Hanada H., Ishizaka H., Ono H., Saitoh M., Fukui K., Fukuda I., Osanai T., and Okumura K. Correlation of oxidative stress with activity of matrix metalloproteinases in patients with coronary artery disease. Possible role for left ventricular remodeling. Eur. Heart J. 24 (2003) 2180-2185
12. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J. Card. Fail. 3 (1997) 249-254
13. Lindsey M., Wedin K., Brown M.D., Keller C., Evans A.J., Smolen J., Burns A.R., Rossen R.D., Michael L., and Entman M. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 103 (2001) 2181-2187
14. 2a in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97 (1998) 1536-1539
15. Matsunaga T., Abe N., Kameda K., Hagii J., Fujita N., Onodera H., Kamata T., Ishizaka H., Hanada H., Osanai T., and Okumura K. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int. J. Cardiol. 105 (2005) 203-208
16. McMurray J., Chopra M., Abdullah I., Smith W.E., and Dargie H.J. Evidence of oxidative stress in chronic heart failure in humans. Eur. Heart J. 14 (1993) 1493-1498
17. Miyamoto S., Nagaya N., Ikemoto M., Tambara K., Kihara Y., Onozawa Y., Hasegawa K., Yamazato A., and Fujita M. Elevation of matrix metalloproteinase-2 level in pericardial fluid is closely associated with left ventricular remodeling. Am. J. Cardiol. 89 (2002) 102-105
18. Mukherjee R., Brinsa T.A., Dowdy K.B., Scott A.A., Baskin J.M., Deschamps A.M., Lowry A.S., Escobar G.P., Lucas D.G., Yarbrough W.M., Zile M.R., and Spinale F.G. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107 (2003) 618-625
19. Nakamura K., Kusano K., Nakamura Y., Kakishita M., Ohta K., Nagase S., Yamamoto M., Miyaji K., Saito H., Morita H., Emori T., Matsubara H., Toyokuni S., and Ohe T. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105 (2002) 2867-2871
20. National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel III) final report. Circulation 106 (2002) 3143-3421
21. Nian M., Lee P., Khaper N., and Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 94 (2004) 1543-1553
22. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
23. Ohara Y., Peterson T.E., and Harrison D.G. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91 (1993) 2546-2551
24. Peterson J.T., Hallak H., Johnson L., Li H., O'Brien P.M., Sliskovic D.R., Bocan T.M., Coker M.L., Etoh T., and Spinale F.G. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103 (2001) 2303-2309
25. Preffer M.A., and Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 81 (1990) 1161-1172
26. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., and Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J. Clin. Invest. 98 (1996) 2572-2579
27. Rohde L.E., Ducharme A., Arroyo L.H., Aikawa M., Sukhova G.H., Lopez-Anaya A., McClure K.F., Mitchell P.G., Libby P., and Lee R.T. Matrix metalloproteinases inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99 (1999) 3063-3070
28. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., and Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335 (1996) 1001-1009
29. Saito S., Fujiwara T., Matsunaga T., Minagawa K., Fukui K., Fukuda I., Osanai T., and Okumura K. Increased adiponectin synthesis in the visceral adipose tissue in men with coronary artery disease treated with pravastatin. A role of the attenuation of oxidative stress. Atherosclerosis 199 (2008) 378-383
30. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
31. Schwartz J.D., Monea S., Marcus S.G., Patel S., Eng K., Galloway A.C., Mignatti P., and Shamamian P. Soluble factor(s) released from neutrophils activates endothelial cell matrix metalloproteinase-2. J. Surg. Res. 76 (1998) 79-85
32. Spinale F.G., Coker M.L., Thomas C.V., Walker J.D., Mukherjee R., and Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ. Res. 82 (1998) 482-495
33. Yasuda S., Miyazaki S., Kinoshita H., Nagaya N., Kanda M., Goto Y., and Nonogi H. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Clin. Sci. 112 (2007) 43-49